Posted by Michael Wonder on 10 Dec 2019
U.S. FDA grants VistaGen Therapeutics fast track designation for PH94B for treatment of social anxiety disorder
10 December 2019 - VistaGen's PH94B is the first drug candidate to be granted U.S. FDA fast track designation for treatment of social anxiety disorder.
VistaGen Therapeutics today announced that the U.S. FDA has granted fast track designation for development of the Company's PH94B neuroactive nasal spray for on-demand treatment of social anxiety disorder (SAD).
After successful Phase 2 development, VistaGen is preparing PH94B for Phase 3 development. PH94B has potential to be the first fast-acting, non-sedating, as-needed treatment for as many as 20 million individuals in the U.S. suffering from SAD.
